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and intima ‑media thickness in carotid (CIMT) or 
femoral arteries.2
CIMT, reflecting vascular age, is independent‑
ly associated with the extent of atherosclerosis 
and ischemic cardiovascular events.3-9 Accord‑
ing to current guidelines, in patients with symp‑
tomatic atherosclerotic lesions and risk factors, 
INTRODUCTION Atherosclerotic progression is 
the main factor responsible for ischemic cardio‑
vascular events, such as major adverse cerebral 
and coronary events (MACCEs), as well as chron‑
ic ischemia.1 There is evidence for a relationship 
between atherosclerotic development and periph‑
eral artery stiffness, and endothelial dysfunction 
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ABSTRACT
INTRODUCTION It is debatable whether the rate of change in carotid intima ‑media thickness (CIMT) may 
be used as a risk indicator of major adverse cerebral and coronary events (MACCEs) in patients with 
either coronary (CAD) and peripheral artery disease (PAD).
OBJECTIVES This prospective study aimed to evaluate the association between CIMT changes and 
the incidence of MACCEs, in patients with symptomatic CAD and PAD.
PATIENTS AND METHODS The study comprised 466 patients admitted with steno ‑occlusive disease, in 
whom revascularization was performed for an index lesion. Group 1 included 305 subjects with CAD, and 
group 2, 161 patients with PAD. CIMT was measured at baseline and at a median of 21 and 41 months 
afterwards. The incidence of MACCE, cardiovascular death (CVD), myocardial infarction (MI), and isch‑
emic stroke was recorded prospectively during 5 years.
RESULTS CIMT increased with a mean (SD) progression rate of 0.027 (0.16) mm/y in group 1 and 
0.026 (0.17) mm/y in group 2 (P = 0.89). CIMT regression was recorded in 112 patients (36.7%) and 
61 patients (37.9%) in groups 1 and 2, respectively, at baseline (P = 0.80), and 82 patients (26.9%) 
and 42 patients (26.1%) in groups 1 and 2, respectively, in follow ‑up (P = 0.85). Maintained CIMT 
regression was independently associated with a reduced risk of MACCEs (hazard ratio [HR], 0.25; 
95% CI, 0.15–0.42), MI (HR, 0.32; 95% CI, 0.20–0.51), ischemic stroke (HR, 0.29; 95% CI, 0.18–0.45), 
and CVD (HR, 0.24; 95% CI, 0.15–0.40), while the CIMT progression rate of 0.056 mm/y was associ‑
ated with an increased risk of MACCEs (sensitivity, 53.2%; specificity, 72.2%; area under the receiver 
operating curve, 0.65).
CONCLUSIONS Maintained CIMT regression is associated with 68% to 75% reduction in the risk of a car‑
diovascular event. However, a long ‑term maintained CIMT regression is achieved in one ‑fourth of patients 
with either CAD or PAD.
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Patients were prescribed long ‑term acetylsal‑
icylic acid or clopidogrel and other medications, 
typically including a statin, β ‑blocker, sartans, 
and angiotensin ‑converting enzyme inhibitor 
(ACEI), as per current European Society Car‑
diology guidelines on the management of sta‑
ble CAD or peripheral artery disease (PAD).10,11
All subjects gave their informed consent pri‑
or to enrollment in accordance with the require‑
ments of the local ethics committee. The study 
was performed in line with the requirements of 
the Declaration of Helsinki.
Laboratory tests Blood samples were collected 
on admission to the Department, prior to any 
intervention, immediately after the signed in‑
formed consent was obtained from the patients. 
The following biochemical parameters were ana‑
lyzed: serum creatinine, total cholesterol, HDL 
cholesterol, LDL cholesterol, high ‑sensitivity 
C ‑reactive protein (hs ‑CRP), and triglycerides.
Carotid intima-media thickness assessment On ad‑
mission, all patients underwent high ‑resolution 
B ‑mode, color Doppler, and pulsed ‑wave Doppler 
ultrasonography of the bilateral carotid arteries. 
The examination was performed using a Toshiba 
Aplio 300 ultrasound machine (Toshiba Medical 
Systems Co, Ltd, Ōtawara, Japan) equipped with 
a 4 to 12 ‑MHz linear array transducer.
The maximum carotid intima ‑media complex 
(CIMT) of the near and far walls was measured 
in the distal 1 cm of the common carotid artery, 
at the bifurcation, and at the level of the inter‑
nal carotid artery and was expressed as the mean 
maximum CIMT.
The CIMT evaluation was repeated in all pa‑
tients twice. The first follow ‑up measurement 
was performed between month 12 and 24 (me‑
dian, 21 months), and the final, between month 
36 and 48 (median, 41 months).
The annual change in CIMT (mm/y) was cal‑
culated by using the following equation: annu‑
al change of CIMT = (follow ‑up CIMT – baseline 
CIMT)/follow ‑up period in years.
The difference between the follow ‑up and base‑
line CIMT was also expressed as an absolute Δ 
value according to the following equation: ΔCIMT 
= follow ‑up CIMT – baseline CIMT.
The ΔCIMT at follow ‑up was interpreted ac‑
cording to the following definition: growth slow‑
ing or regression was defined as ΔCIMT change 
equal to or less than 0.000 mm in every mea‑
surement. Progression was defined as an abso‑
lute CIMT increase above at least 0.001 mm in 
any measurement.
Assessment of atherosclerosis in major arterial ter-
ritories At baseline, all patients were exam‑
ined for concurrent steno ‑occlusive atheroscle‑
rotic disease in other major arteries. Diagnoses 
of CAD, renal, or supra ‑aortic (carotid or ver‑
tebral) artery stenosis, and PAD were based on 
a history of revascularization or the presence of 
rigorous control of risk factors with best medi‑
cal treatment (BMT) and nonpharmacologic in‑
terventions are recommended.10,11
Many pharmacological agents have been 
shown to have beneficial effects on atheroscle‑
rotic plaques, slowing down their growth or even 
enabling plaque regression.12-14 However, it is de‑
batable whether growth slowing or plaque regres‑
sion in CIMT might be related to the substantial 
reduction in the prevalence of MACCEs. Available 
data from previously published studies are un‑
clear.15-16 In patients receiving BMT with CIMT 
progression or regression, the risk of MACCEs 
is still unknown.
Therefore, the main objective of the present 
study was to evaluate whether change in CIMT 
assessed during serial measurements can be re‑
lated to MACCE prevalence in patients with con‑
firmed significant coronary artery disease (CAD) 
or extra coronary lesions exceeding 50% lumen 
reduction. Another goal of the present study was 
to assess what proportion of patients on BMT 
achieved regression in CIMT and whether this 
effect was durable.
PATIENTS AND METHODS This prospective study 
comprised 466 consecutive patients (277 men; 
mean [SD] age, 63.4 [9.6] years) admitted be‑
tween the years 2010 and 2011, with suspected 
symptomatic steno ‑occlusive disease in at least 
1 major arterial territory (including coronary, ca‑
rotid, lower extremities, or renal), referred to our 
institution for further assessment and adequate 
treatment, including BMT and revascularization.
Group 1 comprised 305 patients: 207 men 
(mean [SD] age, 64.5 [9.5] years), with con‑
firmed symptomatic significant CAD (at least 
50% lumen reduction in a major coronary ar‑
tery). Group 2 comprised 161 patients: 70 men 
(mean [SD] age, 61.3 [9.5] years), with no signifi‑
cant CAD but evidence of atherosclerotic lesions 
in the other major arterial territories among ca‑
rotid, renal, or lower extremity arteries exceed‑
ing at least 50% lumen reduction.
The  inclusion and exclusion criteria of 
the study, as well as study design, are present‑
ed in FIGURE 1.
The prevalence of cardiovascular risk factors 
was evaluated. Cardiovascular risk factors were 
defined as hypertension (treated or newly recog‑
nized, based on the average of 3 measurements; 
systolic blood pressure ≥140 mm Hg and/or dia‑
stolic blood pressure ≥90 mm Hg), diabetes mel‑
litus (treated or newly recognized; >11 mmol/l 
[200 mg/dl] in oral glucose tolerance test), hy‑
perlipidemia (treated or newly recognized: to‑
tal cholesterol >4.9 mmol/l [190 mg/dl] and/
or low ‑density lipoprotein cholesterol (LDL) 
>3.0 mmol/l [115 mg/dl] and/or high ‑density 
lipoprotein cholesterol (HDL) men <1.0 mmol/l 
[40 mg/dl], HDL women <1.2 mmol/l [46 mg/dl], 
and/or triglycerides >1.7 mmol/l [150 mg/dl]).17 
Smoking was defined as current smoking or ac‑
tive smoking within the past 5 years.
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466 consecutive patients with symptomatic steno‑occlusive arterial disease (≥50% lumen reduction) in major territories including coronary, 
renal, carotid and/or lower extremity arteries, who underwent index lesion revascularization, admitted between years 2010 and 2011
(277 men; mean [SD] age, 63.4 [9.6] years)
Exclusion criteria: chronic or acute inflammatory status, active cancer, critical state, acute heart failure 
or congestive heart failure in New York Heart Association class IV, anticoagulant therapy, lack of consent 
to participate in the study, or suboptimal carotid artery ultrasound (eg, massive calcifications making CIMT 
assessment unfeasible), lack of at least one follow‑up CIMT reassessment
Inclusion criteria: documented significant lumen reduction of ≥50% in at least one major arterial territory, 
age over 18 years, informed consent to participate in the study
Group 1 (305 subjects)
207 men, mean (SD) age, 64.5 (9.5) years, with 
angiographically confirmed symptomatic significant CAD, 
who underwent endovascular revascularization of index lesion
Final CIMT reassessment in patients
between month 36 and 48 after discharge, with 
assessment of new cardiovascular events incidence 
(448 patients)
Final follow‑up phone interview between 
month 55 and 65 (420 patients)
Patients lost‑to‑follow up, but alive 
according to Social Insurance Institution
(11 patients)
Group 2 (161 subjects) 
70 men, mean (SD) age, 61.3 (9.5) years, with no signifi‑
cant CAD, but with angiographically documented athero‑
sclerotic lesions in extra coronary arterial territories, who 
underwent endovascular revascularization of index lesion
Baseline CIMT assessment, data collection on 
pharmacotherapy and cardiovascular risk factors 
presence, as well as blood test results before 
hospital discharge  
(466 subjects)
Follow‑up CIMT assessment
between month 12 and 24 after discharge, with 
assessment of cardiovascular events incidence (466 
subjects)
Cardiovascular death  
(9 patients)
Noncardiovascular death 
(9 patients)
Cardiovascular death  
(9 patients)
Noncardiovascular death 
(8 patients)
FIGURE 1 Study design, inclusion and exclusion criteria 
Abbreviations: CIMT, carotid intima ‑media thickness; others, see TABLE 1
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by a Cox univariate hazard analysis, and in cases 
with a trend towards a difference (P < 0.05), they 
were included in a multivariate stepwise Cox pro‑
portional hazards analysis. The results of the lat‑
ter were expressed as hazard ratio (HR) and 95% 
confidence interval (CI). Receiver operating char‑
acteristic (ROC) curves were constructed to es‑
tablish the best cutoff value for annual CIMT pro‑
gression rate predicting risk of MACCEs. The area 
under the ROC curve (AUC) was calculated. Statis‑
tical analyses were performed with Statistica ver‑
sion 12.0 software (StatSoft, Inc, Tulsa, Oklaho‑
ma, United States). A P value of less than 0.05 was 
considered significant.
RESULTS Subjects in group 1, as compared 
to group 2 were significantly older (P <0.001), 
showed a significant increase in prevalence of 
classic cardiovascular risk factors such as: hyper‑
tension (P = 0.02), diabetes (P = 0.002), hyperlip‑
idemia (P <0.001), smoking (P = 0.01), and had 
a higher number of arterial territories with sub‑
stantial stenosis (P <0.001) (TABLE 1). The detailed 
clinical characteristics and assessment of con‑
current substantial atherosclerosis of the study 
group are summarized in TABLE 1. On discharge, 
long ‑term acetylsalicylic acid and/or clopidogrel 
was given in all subjects; ACEI, in 74.6%; sar‑
tans, in 5.4%; β ‑blocker, in 72.4%; statins, in 
94.6%; fibrates, 2.5%; ezetimibe, 3.2%; diuret‑
ics, 46.9%; and calcium channel blockers, in 46.9% 
of the patients.
The baseline mean (SD) CIMT value in group 
1 was higher than in group 2: 1.475 (0.42) vs 
1.318 (0.44), P <0.001, as well as mean CIMT val‑
ues after the first and second re ‑evaluation follow‑
‑up CIMT (FIGURE 2).
During the first follow ‑up visit, the mean 
CIMT value regression was found in 112 patients 
(36.7%) in group 1 and in 61 patients (37.9%) in 
group 2 (P = 0.80), while in the remaining pa‑
tients, CIMT progression was observed despite 
BMT (FIGURE 3).
On final CIMT reassessment, CIMT regression 
was maintained in 82 patients (26.9%) in group 
1 and in 42 patients (26.1%) in group 2, while 
CIMT progression was observed in 223 patients 
(73.1%) and 119 patients (73.9%), respectively 
(P = 0.85) (FIGURE 3).
Overall, the mean CIMT value was progress‑
ing, with a mean (SD) progression rate sim‑
ilar in both groups: +0.027  (0.16)  mm/y vs 
+0.026 (0.16) mm/y; P = 0.89. CIMT progression 
was related to significantly higher incidence of 
MACCEs, MI, and IS in both groups, as compared 
with patients with CIMT regression (FIGURE 4).
CIMT progression was an independent risk 
factor of future MACCEs in multivariate step‑
wise regression analysis (RR, 1.22; 95% CI, 1.03–
1.44; P <0.001). In the ROC analysis, the annu‑
al mean CIMT progression rate of 0.056 mm/y 
was the best predictor of MACCEs; however, this 
had moderate sensitivity (53.2%) and specificity 
(72.2%) (AUC, 0.646). Data are shown in FIGURE 5.
substantial atherosclerotic lesions. This was de‑
fined as at least 50% vascular lumen reduction in 
the corresponding territory as assessed by duplex 
ultrasonography, computed tomography angiog‑
raphy, or invasive angiography.
Additionally, the ankle–brachial index was rou‑
tinely evaluated in all patients as a screening tool 
for PAD, with a cut off value of less than 0.9. Ver‑
ification of PAD diagnosis with Doppler ultra‑
sound was performed in all cases with an ankle–
brachial index of less than 0.9.
Stenoses of carotid, renal, and lower extrem‑
ity arteries assessed as substantial by Doppler 
ultrasound based on the peak systolic and end‑
‑diastolic velocities were then verified by angi‑
ography or computed tomography angiography.
Coronary and peripheral angiography was per‑
formed from radial or femoral vascular access us‑
ing a Coroscop system (Siemens AG, Munich, Ger‑
many) equipped with Quantcor version 4.0 quan‑
titative analysis software. Angiography was per‑
formed in at least 2 orthogonal projections that 
best displayed the lesion.
Follow -up period During the mean (SD) follow‑
‑up of 57 (25) months (range, 13–84 months), 
the incidence of all MACCEs, including myocar‑
dial infarction (MI), ischemic stroke (IS), and car‑
diovascular death (CVD) were recorded.
MI was diagnosed according to the current cri‑
teria of the European Society of Cardiology.18 
The diagnosis of IS was established by a neurol‑
ogist to ensure validity. CVD was defined as fa‑
tal IS, fatal MI, or other CVD (ie, any sudden or 
unexpected death unless proven as noncardio‑
vascular on autopsy).
Data on MACCEs were collected during the ul‑
trasound visits. As the study was continued be‑
yond the last CIMT assessment, the final visit had 
a form of a telephone conversation with a patient 
or a family member. The survival status of pa‑
tients lost to follow‑up (n = 11) was determined 
on the basis of data obtained from the national 
health registry.
Patients were encouraged to adhere to the 
medications prescribed on discharge and inten‑
sify their efforts to achieve therapeutic goals. 
They were recommended to continue the Medi‑
terranean diet and implement lifestyle changes 
throughout the follow ‑up.
Statistical analysis We analyzed the effect of 
CIMT change and patient ‑related factors on 
the incidence of the following endpoints: MAC‑
CEs, MI, IS, and CVD.
The t test was used for a comparison of continu‑
ous variables, and the χ2 test was used to compare 
proportions of categorical variables. The means of 
the analyzed parameters across the groups were 
tested by the analysis of variance. Frequencies 
were compared by the χ2 test for independence.
To establish the factors that could affect MAC‑
CEs, MI, IS, and CVD incidence, the clinical, pro‑
cedural, and angiographic variables were assessed 
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factor of MACCEs, CVD, IS, and MI associated 
with risk reduction (TABLE 2). Also, history of hy‑
perlipidemia (P = 0.005), cigarette usage (P = 
0.0005), and male sex (P = 0.046) were associ‑
ated with MACCEs. The association of MI risk 
with smoking tended to be significant (P = 0.08).
In a multivariate stepwise Cox proportional 
hazards analysis, the maintained CIMT regres‑
sion on two consecutive follow ‑up visits was inde‑
pendently associated with a reduced risk of MAC‑
CEs (HR, 0.25; 95% CI, 0.15–0.42; P <0.001), MI 
(HR, 0.32; 95% CI, 0.20–0.51; P <0.001), IS (HR, 
0.29; 95% CI, 0.18–0.45; P <0.001), and CVD (HR, 
0.24; 95% CI, 0.15–0.40; P<0.001). Other inde‑
pendent predictors of MACCEs, CVD, MI, and IS 
are given in FIGURE 6.
DISCUSSION The major finding of the present 
study, conducted on revascularized patients on 
BMT with significant CAD or PAD, is that main‑
tenance of CIMT regression on consecutive ul‑
trasonographic examinations during the median 
21‑ and 41 ‑month follow ‑up, is associated with 
a significant reduction in risk of MACCEs, MI, 
IS, and CVD, as compared to CIMT progression. 
Unfortunately, the maintained CIMT regression 
was noted in approximately one‑fourth of our 
study participants.
The number of patients who achieve CIMT re‑
duction varies in reported studies. In a study by 
Bovesky et al, regression of common CIMT was 
noted in only 7.8% of patients with type 2 dia‑
betes.19 The MITEC trial20 showed a reduction in 
CIMT in 56.5% of patients on candesartan and 
59% on amlodipine. Also, Schneider et al21 showed 
a significant, BMT ‑induced reduction of the com‑
mon CIMT in a group of 298 patients with non– 
–ST ‑segment elevation MI at 12 months in com‑
parison with the baseline values.21
However, in the  aforementioned studies, 
CIMT assessment was performed only once dur‑
ing the follow ‑up.
Our study also indicated that only maintenance 
of CIMT regression is a really valuable marker of 
lower cardiovascular event risk. Maintained CIMT 
regression, in comparison with CIMT progres‑
sion, was associated with a 68% to 76% reduc‑
tion in cardiovascular risk in a multivariate Cox 
proportional hazards analysis during the 5 ‑year 
follow ‑up.
In the Cholesterol Lowering Atherosclero‑
sis Study (CLAS) trial,20 featuring therapy with 
colestipol ‑niacin, a lower rate of change in com‑
mon CIMT over time was related to a lower risk 
of an event during the 8.8 ‑year follow ‑up.20 Pa‑
tients with an annual common CIMT progres‑
sion rate of 0.034 mm/y had a 2.9 ‑fold higher 
CVD risk compared with those with a common 
CIMT progression rate of 0.011 mm/y or less.22
However, the present study indicated that 
nearly three ‑fourth of patients had CIMT pro‑
gression despite receiving treatment. This propor‑
tion remained similar in both study groups and 
was related to a significantly higher prevalence of 
The Cox univariate regression analysis indicat‑
ed that maintained mean CIMT regression during 
follow ‑up visits is a potentially better prognostic 
TABLE 1 Baseline characteristics of the study group (n = 466)
Parameter All patients 
(n = 466)
Group 1
CAD (+) 
(n = 305)
Group 2
PAD (+) 
(n = 161)
P value
Demographic data
Age, y, mean (SD); range 63.4 (9.6); 
0–89
64.5 (9.5); 
37–89
61.3 (9.5); 
0–87
<0.001
Male sex, n (%) 277 (59) 207 (68) 70 (43) <0.001
Clinical data, n (%)
Hypertension 436 (94) 291 (95) 145 (90) 0.02
Diabetes mellitus 140 (30) 106 (35) 34 (21) <0.01
Hyperlipidemia 415 (89) 285 (93) 130 (81) <0.001
Smoking (current or in 
the past 5 years)
257 (55) 181 (59) 76 (47) 0.01
Body mass index, kg/m2, 
mean (SD)
27.5 (3.9) 27.6 (3.9) 27.4 (3.8) 0.72
Previous MI 155 (33.3) 155 (51) 0 <0.001
Previous IS 106 (23) 67 (22) 39 (24) 0.58
Number of coronary arteries with >50% stenosis, n (%)
1 ‑vessel CAD 107 (22) 107 (35.1) NA NA
2 ‑vessel CAD 63 (14) 63 (21)
3 ‑vessel CAD 135 (29) 135 (45)
Number of arterial territories with lumen reduction >50%
1 territory, n (%) 165 (32) 61 (20) 116 (72) <0.001
2 territories, n (%) 156 (33) 135 (44) 32 (20)
3 territories, n (%) 91 (19) 83 (27) 13 (8)
4 territories, n (%) 25 (5) 26 (9) 0
Ankle –brachial index,  
mean (SD)
0.96 (0.21) 1.05 (0.20) 0.84 (0.21) <0.001
LVEF, %, mean (SD) 58 (10) 56 (10) 63 (9) <0.001
Laboratory data, mean (SD)
hs ‑CRP, mg/l 4.62 (8.43) 5.06 (9.7) 3.8 (5.2) 0.09
Creatinine, µmol/l 93.3 (33.2) 96.8(33.1) 86.5 (32) 0.004
TC, mmol/l 4.84 (1.18) 4.87 (1.2) 4.77 (1.05) 0.47
LDL ‑C, mmol/l 2.91 (0.97) 2.94 (1.0) 2.84 (0.94) 0.31
HDL ‑C, mmol/l 1.25 (0.35) 1.22 (0.3) 1.32 (0.35) 0.31
Triglycerides, mmol/l 1.59 (1.05) 1.64 (1.2) 1.48 (0.73) 0.05
Medications prescribed on discharge, n (%)
Acetylsalicylic acid / 
clopidogrel
466 (100) 305 (100) 161 (100) 1.00
ACEI 348 (74.6) 265 (86.9) 79 (49.1) <0.001
Sartan 25 (5.4) 12 (3.9) 13 (8.1) 0.06
β ‑blocker 338 (72.5) 254 (83.3) 84 (52.2) <0.001
Statin 441 (94.6) 295 (96.7) 146 (90.7) 0.006
Fibrate 12 (2.5) 8 (2.6) 4 (2.5) 0.92
Ezetimibe 15 (3.2) 3 (0.9) 12 (7.4)) <0.001
Diuretic 219 (46.9) 151 (49.5) 68 (42.2) 0.13
Calcium channel blocker 218 (46.8) 132 (43.3) 86 (53.4) 0.037
Abbreviations: ACEI, angiotensin ‑converting ‑enzyme inhibitor; CAD, coronary artery 
disease; HDL ‑C, high ‑density lipoprotein cholesterol; hs‑CRP, high‑sensitivity C‑reactive 
protein; IS, ischemic stroke; LDL ‑C, low ‑density lipoprotein cholesterol; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; PAD, 
peripheral artery disease; TC, total cholesterol
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≥1.1 mm) at baseline.24 Researchers found that 
fast max ‑aggregate CIMT progression after 
6 months (2nd CIMT test) was a significant pre‑
dictor of coronary events during a 2 ‑year follow‑
‑up after adjustment for known risk factors (HR 
per 0.1 ‑mm increase over 6 months, 1.21; 95% 
CI, 1.10–1.33; P = 0.0001).25 In that study, ROC 
curves showed that the addition of the change in 
plaque ‑CIMT max to conventional risk factors re‑
sulted in a greater AUC compared with conven‑
tional Framingham risk factors alone (0.81 and 
0.70, respectively, P = 0.02).24
Interestingly, in the IMPROVE study,25 the as‑
sessment of the 15 ‑month progression demon‑
strated that only the fastest CIMT maximum pro‑
gression was significantly associated with the risk 
of subsequent vascular events.25 Yet, Bartman et 
MACCEs. Although the annual mean CIMT pro‑
gression rate of 0.056 mm/y was the best predic‑
tor of MACCEs, it was characterized by a relative‑
ly low sensitivity (53.2%) and specificity (72.2%).
Consistent with our results, Okayama et al23 
observed that a higher median progression rate 
of common CIMT (0.03 mm/y) was a signifi‑
cant determinant of MACCEs (HR, 2.24; 95% 
CI, 1.25–4.03; P <0.01) during a mean follow ‑up 
of 7.6 years (in a multivariate Cox proportion‑
al hazard model). Additionally, the combination 
of high baseline CIMT (above 1.1 mm) and high 
CIMT progression (>0.034 mm/y) was a signifi‑
cant predictor of MACCEs.23
A higher clinical value of CIMT was found 
in a study by Hirano et al,24 including 240 pa‑
tients with CAD who had a carotid plaque (CIMT 
FIGURE 2 Initial mean 
carotid intima ‑media 
thickness (CIMT) value 
and CIMT changes 
during follow ‑up visits
FIGURE 3 Proportion 
of patients in group 
1 and group 2 in whom 
carotid intima ‑media 
thickness (CIMT) 
regression vs 
progression was 
observed at a median 
follow‑up (FU) of 
21 months and 
41 months
0
0.25
Group 1 Group 2
Baseline mean CIMT Mean CIMT at 21 months Mean CIMT at 41 months
0.75
0.5
1
1.25
1.475
1.318
1.554
1.385
1.593
1.4421.5
1.75
2
P <0.001 P <0.001 P <0.001
CI
M
T,
 m
m
36.7
63.3
37.9
62.1
26.9
73.1
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cardiovascular events.27 Also, in the present study, 
the inclusion of carotid plaque into CIMT mea‑
surement was shown to be an important prog‑
nostic marker. This is in line with a recent meta‑
‑analysis showing that carotid plaque, compared 
with CIMT, more accurately predicts coronary ar‑
tery disease events.28
The potential advantage of CIMT changes mon‑
itoring is the reassessment of risk in an individual 
patient. Of note, CIMT progression or regression 
is a complex process, as it depends on multiple 
al26 reported that, unlike CIMT, the carotid plaque 
score was independently associated with micro‑
angiopathic complications in type 2 diabetes.26
A different approach to CIMT assessment 
was presented by Wannarong et al.27 They ob‑
served that progression of total carotid plaque 
area at 1 ‑year follow ‑up was a significant predic‑
tor of vascular events after adjustment for cor‑
onary risk factors (P = 0.001), but the progres‑
sion or regression of the CIMT itself did not pre‑
dict IS, transient ischemic attack, death, or any 
FIGURE 4 Number of 
patients with major 
adverse cerebral and 
coronary events, 
myocardial infarction, 
and ischemic stroke 
depending on 
the observed change in 
final follow ‑up carotid 
intima ‑media thickness 
(CIMT) assessment with 
respect to significant 
coronary artery disease 
presence on initial 
coronary angiography 
Abbreviations: MACCE, 
major adverse cerebral 
and coronary events; 
others, see TABLE 1
FIGURE 5 A receiver 
operating characteristic 
curve (ROC) for annual 
carotid intima ‑media 
thickness (CIMT) 
progression and major 
adverse cerebral and 
coronary events 
Abbreviations: AUC, area 
under the receiver 
operating characteristic 
curve
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In conclusion, we showed that repeated assess‑
ment of CIMT changes during follow ‑up both in 
patients with CAD and substantial PAD might be 
a valuable tool for cardiovascular event risk as‑
sessment in individual subjects. We demonstrated 
that a durable CIMT regression effect is achieved 
in only one ‑fourth of subjects. However, main‑
tained CIMT regression is a more valuable clini‑
cal marker of treatment efficacy, related to lower 
cardiovascular event risk, as compared to CIMT 
progression which is only moderately associated 
with increased risk of MACCEs.
Study limitations The length of CIMT measure‑
ment intervals was not pre defined. Only base‑
line risk factor levels and medications were used 
for all analyses. The aim of the study was not to 
investigate links between achieved therapeutic 
goals, CIMT changes and their effect on MACCE.
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factors.29,30 The final effect on CIMT depends on 
the action of proatherosclerotic demographic, 
cardiovascular, and genetic risk factors as well as 
the achievement of the therapeutic goals through 
the use of medications and lifestyle changes. From 
this perspective, CIMT changes only demonstrate 
whether our pharmacological and nonpharmaco‑
logical interventions are sufficient to limit athero‑
sclerosis progression or not. CIMT does not sup‑
port any data on which the mechanism of athero‑
sclerosis progression is a key factor in an individu‑
al patient. Probably, for these reasons, in the cur‑
rent study, statins failed to show an independent 
effect on MACCE incidence. The same finding 
was reported by Hirano et al,24 who demonstrat‑
ed that CIMT changes, despite antiatherosclerot‑
ic therapy, are independently associated with fu‑
ture coronary events. Moreover, the use of statin 
and ACEI or sartans had no significant incremen‑
tal effect on predicting future coronary events.24
Thus, the possible role of a change in the CIMT 
is to warrant a closer “look” at patient compli‑
ance and improve medications to achieve ther‑
apeutic goals.
TABLE 2 Associations between clinical, laboratory, and carotid intima ‑media thickness parameters and major 
adverse cerebral and coronary events, myocardial infarction, ischemic stroke, and cardiovascular death in univariate 
Cox proportional hazards analysis
Parameter MACCE CVD MI IS
Mean CIMT regression on 
the first follow ‑up visit
0.249 (0.15–0.39); 
<0.001
0.42 (0.28–0.63); 
<0.001
0.37 (0.24–0.58); 
<0.001
0.29 (0.19–0.46); 
<0.001
Maintained mean CIMT 
regression on the final 
visit
0.311 (0.19–0.49); 
<0.001
0.46 (0.31–0.67); 
<0.001
0.41 (0.27–0.63); 
<0.001
0.36 (0.24–0.54); 
<0.001
Age 1.02 (1.01–1.02); 
<0.001
1.02 (1.01–1.04); 
<0.001
1.02 (1.01–1.08); 
<0.001
1.02 (1.01–1.04); 
<0.001
Female sex 0.80 (0.65–0.98); 
<0.001
0.86 (0.71–1.04); 
0.13
0.79 (0.65–0.97); 
0.02
0.89 (0.73–1.08); 
0.26
Hypertension 0.96 (0.63–1.45); 
0.84
0.93 (0.64–1.35); 
0.71
1.01 (0.69–1.49); 
0.92
0.84 (0.58–1.28); 
0.47
Diabetes mellitus 1.00 (0.79–1.26); 
0.96
0.97 (0.79–1.19); 
0.77
0.95 (0.77–1.73); 
0.67
0.99 (0.80–1.22); 
0.96
Hyperlipidemia 1.37 (1.01–1.89); 
0.048
1.21 (0.90–1.63); 
0.20
1.27 (0.99–1.730; 
0.13
1.31 (0.97–1.76); 
0.08
Smoking 1.21 (0.98–1.49); 
0.06
1.11 (0.93–1.34); 
0.25
1.16 (0.95–1.42); 
0.13
1.13 (0.93–1.37); 
0.049
Creatinine 1.00 (0.99–1.00); 
0.19
1.00 (0.99–1.00); 
0.13
1.00 (0.99–1.00); 
0.29
1.00 (0.99–1.01); 
0.08
hs ‑CRP 0.99 (0.98–1.01); 
0.04
0.99 (0.98–1.01); 
0.54
0.99 (0.98–1.01); 
0.79
0.99 (0.98–1.01); 
0.51
TC 1.00 (0.99–1.00); 
0.59
1.00 (0.99–1.00); 
0.69
1.00 (0.99–1.00); 
0.21
1.00 (0.99–1.00); 
0.68
LDL ‑C 1.00 (0.99–1.00); 
0.18
1.00 (0.99–1.00); 
0.26
1.00 (0.99–1.00); 
0.21
1.00 (0.99–1.00); 
0.24
HDL ‑C 1.00 (0.99–1.00); 
0.18
1.00 (0.99–1.00); 
0.24
1.00 (0.99–1.00); 
0.21
1.00 (0.99–1.00); 
0.23
Glucose 1.02 (0.94–1.11); 
0.57
1.02 (0.95–1.09); 
0.57
1.02 (0.95–1.11); 
0.48
1.01 (0.93–1.09); 
0.78
Statin use 0.53 (0.20–1.48); 
0.23
0.01 (0.00–996); 
0.99
0.64 (0.21–2.03); 
0.45
0.32 (0.04–2.31); 
0.26
Data are presented as HR (95% CI); P value.
Abbreviations: CVD, cardiovascular death; others, see TABLE 1, FIGURES 1 and 3
POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (1)20
REFERENCES
1 Libby P, Theroux P. Pathophysiology of coronary artery disease. Circula‑
tion. 2005; 111: 3481‑3488. 
2 Aslan AN, Özcan AN, Ayhan H, et al. Evaluation of local carotid stiffness 
and inflammatory biomarkers in stable angina pectoris. Adv Interv Cardiol. 
2017; 13: 122‑129. 
3 Kablak ‑Ziembicka A, Przewlocki T, Pieniazek P, et al. The role of carot‑
id intima ‑media thickness assessment in cardiovascular risk evaluation in 
patients with polyvascular atherosclerosis. Atherosclerosis. 2010; 209: 
125‑130. 
4 Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart 
disease incidence with carotid arterial wall thickness and major risk fac‑
tors: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemi‑
ol. 1997; 146: 483‑494. 
5 O’Leary DH, Polak JF, Kronmal RA, et al. Carotid ‑artery intima and me‑
dia thickness as a risk factor for myocardial infarction and stroke in older 
adults. Cardiovascular Health Study Collaborative Research Group. N Engl 
J Med. 1999; 340: 14‑22.
6 Rosvall M, Janzon L, Berglund G, et al. Incident coronary events and 
case fatality in relation to common carotid intima ‑media thickness. J Intern 
Med. 2005; 257: 430‑437. 
7 Poredos P. Intima ‑media thickness: indicator of cardiovascular risk and 
measure of the extent of atherosclerosis. Vasc Med. 2004; 9: 46‑54. 
8 Wrotniak L, Kablak ‑Ziembicka A, Karch I, et al. Multiterritory atheroscle‑
rosis and carotid intima ‑media thickness as cardiovascular risk predictors af‑
ter percutaneous angioplasty of symptomatic subclavian artery stenosis. J 
Ultrasound Med. 2016; 35: 1977‑1984. 
9 Hrycek E, Banasiewicz ‑Szkróbka I, Żurakowski A, et al. Selected adipo‑
kines and thickness of the intima ‑media complex in patients with systemic 
lupus erythematosus. Kardiol Pol. 2018; 76: 917‑919. 
10 European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, 
et al. ESC Guidelines on the diagnosis and treatment of peripheral artery 
diseases: Document covering atherosclerotic disease of extracranial ca‑
rotid and vertebral, mesenteric, renal, upper and lower extremity arteries: 
the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseas‑
es of the European Society of Cardiology (ESC); ESC Committee for Practice 
Guidelines. Eur Heart J. 2011; 32: 2851‑2906. 
11 Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on 
the management of stable coronary artery disease. The Task Force on 
the management of stable coronary artery disease of the European Society 
of Cardiology. Eur Heart J. 2013; 34: 2949‑3003.
12 Yokoi H, Nohara R, Daida H, et al. Change in carotid intima ‑media 
thickness in a high ‑risk group of patients by intensive lipid ‑lowering ther‑
apy with rosuvastatin: subanalysis of the JART study. Int Heart J. 2014; 
55: 146‑152. 
13 Riccioni G. The effect of antihypertensive drugs on carotid intima me‑
dia thickness: an up ‑to ‑date review. Curr Med Chem. 2009; 16: 988‑996. 
14 Baldassarre D, Hamsten A, Veglia F, et al. Measurements of carotid 
intima ‑media thickness and of interadventitia common carotid diameter im‑
prove prediction of cardiovascular events: results of the IMPROVE (carotid 
intima media thickness [IMT] and IMT ‑progression as predictors of vascu‑
lar events in a high risk European population) study. J Am Coll Cardiol. 2012; 
60: 1489‑1499. 
15 Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima ‑media thickness 
progression to predict cardiovascular events in the general population (the 
PROG ‑IMT collaborative project): a meta ‑analysis of individual participant 
data. Lancet. 2012; 379: 2053‑2062. 
2018 (doi.org/10.1093/eurheartj/ehy566.6154) 
and the International Congress of the Polish Car‑
diac Society in Kraków 2018.
CONTRIBUTION STATEMENT JG contributed to 
study concept and design, performance of ex‑
aminations, CIMT measurements, data collec‑
tion, obtaining the informed consent, obtaining 
blood samples and preparing biological material 
for further laboratory analyses, and manuscript 
writing. TP contributed to study concept and de‑
sign, work supervision, interpretation of data for 
the final approval of the version to be published, 
responsibility for data integrity supervision. JP 
and RB performed examinations, collected data 
for statistical analyses, and drafted the article. 
PP contributed to analysis and editing assistance, 
as well as critical revision for important intellec‑
tual content. SM contributed to data collection 
for statistical analyses and manuscript drafting. 
WR contributed to critical revision for important 
intellectual content, and statistical analysis. KŻ 
contributed to the assessment of coronary an‑
giographies, writing and editing assistance, and 
critical revision of the work. AK ‑Z contributed to 
study concept and design, obtaining funds, anal‑
ysis and interpretation of the data, CIMT mea‑
surements and data reproducibility, manuscript 
writing, and was responsible for all aspects of 
the work, its integrity and accuracy, and appro‑
priateness of investigations and resolves, as well 
as the final manuscript approval.
OPEN ACCESS This is an Open Access article dis‑
tributed under the terms of the Creative Com‑
mons Attribution ‑NonCommercial ‑ShareAlike 
4.0 International License (CC BY ‑NC ‑SA 4.0), 
allowing third parties to copy and redistribute 
the material in any medium or format and to 
remix, transform, and build upon the material, 
provided the original work is properly cited, dis‑
tributed under the same license, and used for non‑
commercial purposes only. For commercial use, 
please contact the journal office at pamw@mp.pl.
FIGURE 6 Independent 
associations between 
clinical, laboratory, and 
carotid intima–media 
thickness parameters 
and major adverse 
cerebral and coronary 
events, myocardial 
infarction, ischemic 
stroke, and 
cardiovascular death in 
multivariate Cox 
proportional hazards 
analysis. 
Abbreviations: see 
TABLE 1, TABLE 2, 
FIGURE 1, and FIGURE 4
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